YTHDF1-mediated glutamine metabolism via GLS1 has been shown to promote cisplatin chemoresistance in CRC cells, while the combination of YTHDF1 silencing and cisplatin leads to synergistic effect in suppressing tumor growth [35]. This evidence concerns the gene YTHDF1 and neoplasm.